Comment on CMS-2026-1256-0002

Summary: Enovis, a medical technology company, supports the proposed rule but urges CMS to include specific cost exclusions for non-opioid pain management products (like their IceMan device) under the TEAM and CJR-X payment models. They argue that without these exclusions, hospitals may be financially disincentivized from using effective non-opioid treatments in favor of cheaper opioids. Additionally, the company requests that CMS delay expanding the TEAM model to ambulatory surgery centers (ASCs) until further stakeholder engagement occurs to address systemic differences in payment policy.